Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Rocket Pharmaceuticals Inc
(NQ:
RCKT
)
18.59
+0.10 (+0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
662,935
Open
18.50
Bid (Size)
18.50 (1)
Ask (Size)
18.80 (2)
Prev. Close
18.49
Today's Range
18.17 - 18.92
52wk Range
15.13 - 32.52
Shares Outstanding
65,837,894
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024
August 05, 2024
RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
August 05, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
-36.98%
-36.98%
1 Month
-28.17%
-28.17%
3 Month
-11.22%
-11.22%
6 Month
-37.60%
-37.60%
1 Year
+17.36%
+17.36%
More News
Read More
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
June 28, 2024
Via
Benzinga
Exposures
Product Safety
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 28, 2024
Via
Benzinga
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
June 28, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Rocket Pharmaceuticals
November 07, 2023
Via
Benzinga
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
June 14, 2024
Via
Talk Markets
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
May 29, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 10, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024
May 06, 2024
Via
InvestorPlace
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 06, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
April 02, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
March 26, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
February 26, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
February 13, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
7 Speculative Stocks to Double Your Money THIS Year
January 22, 2024
Via
InvestorPlace
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
December 12, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
December 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 06, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Stock Sees Improved Price Strength
November 02, 2023
Via
Investor's Business Daily
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
October 27, 2023
Via
Investor's Business Daily
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 19, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
October 02, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.